Elsa Pennese: Influence Statistics

Elsa Pennese

Elsa Pennese

U.O.S.D. Centro Diagnosi e Terapia dei Linfomi, Dipartimento Oncologico-Ematologico, Presidio Ospedaliero "Spirito Santo", Pescara | Lymphoma Unit, Department of Hematology, ...

Elsa Pennese: Expert Impact

Concepts for which Elsa Pennese has direct influence: Platelet activation , Vivo formation , Geriatric assessment , Targeted drugs , Diabetes mellitus , Patients cll , Diffuse large .

Elsa Pennese: KOL impact

Concepts related to the work of other authors for which for which Elsa Pennese has influence: Oxidative stress , Lipid peroxidation , Diabetes mellitus , Platelet activation , Type 2 , Diabetic patients , Cardiovascular disease .

KOL Resume for Elsa Pennese

Year
2022

U.O.S.D. Centro Diagnosi e Terapia dei Linfomi, Dipartimento Oncologico-Ematologico, Presidio Ospedaliero "Spirito Santo", Pescara

2021

Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara, Italy.

2019

Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara, Italy

1999

From the Departments of Medicine and Aging (G.D., A.C., A.M., S.S., E.P., E.V., F. Costantini, F. Capani, C.P.) and Biomedical Sciences (T.B.), University of Chieti “G. D’Annunzio” School of Medicine; the Division of Internal Medicine, Civil Hospital of Popoli (A.F.); and the Department of Pharmacology (G.C.), Catholic University School of Medicine; Rome, Italy.

Prominent publications by Elsa Pennese

KOL-Index: 12941 . BACKGROUND: Diabetes mellitus (DM) is associated with enhanced lipid peroxidation and persistent platelet activation. We tested the hypothesis that the in vivo formation of the F2-isoprostane 8-iso-prostaglandin (PG)F2alpha, a bioactive product of arachidonic acid peroxidation, is enhanced in DM and contributes to platelet activation. METHODS AND RESULTS: Urine samples were obtained from ...
Known for Platelet Activation | Diabetes Mellitus | Vivo Formation | 8 Iso
KOL-Index: 4957 . PURPOSE: To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). METHODS: We conducted the prospective Elderly Project study on patients with DLBCL older than 64 years who underwent our Fondazione Italiana Linfomi original geriatric assessment (oGA) ...
Known for Geriatric Assessment | Diffuse Large | Patients Dlbcl | Cell Lymphoma
KOL-Index: 4745 . Autoimmune cytopenias (AICs) affect 5% to 9% of patients with chronic lymphocytic leukemia (CLL). Targeted drugs-ibrutinib, idelalisib, and venetoclax-have a prominent role in the treatment of CLL, but their impact on CLL-associated AICs is largely unknown. In this study, we evaluated the characteristics and outcome of preexisting AICs and described the incidence, quality, and management ...
Known for Targeted Drugs | Patients Cll | Venetoclax Therapy | Treated Ibrutinib

Key People For Platelet Activation

Top KOLs in the world
#1
Alan D Michelson
platelet activation flow cytometry aspirin resistance
#2
Sanford J Shattil
alpha iib platelet activation tyrosine phosphorylation
#3
Meinrad Paul Gawaz
platelet activation endothelial cells thrombus formation
#4
Zaverio M Ruggeri
willebrand factor platelet adhesion thrombus formation
#5
Bernhard Nieswandt
thrombus formation platelet activation ischemic stroke
#6
Denisa D Wagner
willebrand factor endothelial cells deep vein thrombosis

U.O.S.D. Centro Diagnosi e Terapia dei Linfomi, Dipartimento Oncologico-Ematologico, Presidio Ospedaliero "Spirito Santo", Pescara | Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara, Italy. | Unità Operativa Semplice Dipartime